



JC04 Rec'd PCT/PTO 0.3 AUG 2005 *pc*

*A3*

PATENT

Attorney Docket No. P07181US00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: **AGGER, Nicolai**  
SERIAL NO: 10/532,698  
FILED: April 26, 2005  
TITLE: COMPOSITION FOR TREATMENT OF GASTROINTESTINAL DISORDERS

**INFORMATION DISCLOSURE STATEMENT  
FILED WITHIN THREE MONTHS OF FILING OR  
BEFORE MAILING OF FIRST OFFICE ACTION (37 C.F.R. § 1.97(b))**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

This information disclosure statement is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office Action on the merits, or before the mailing of a first office action after the filing of a request for continued examination, whichever event occurs last.

Attached are Forms PTO/SB/08B (formerly Form PTO-1449) listing the relevant art known to the applicant herein. Copies of non-U.S. patents are enclosed. References that are U.S. patents are not required to be submitted. The Examiner is requested to consider the references and make them of record.

=====

CERTIFICATE OF MAILING/TRANSMISSION (37 CFR 1.8(a))

I hereby certify that this correspondence is, on the date shown below, being:

MAILING

☒ deposited with the United States Postal Service with sufficient postage as First Class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: August 1, 2005

FACSIMILE

☐ transmitted by facsimile to the Patent and Trademark Office, Art Unit \_\_\_\_\_ at Fax No. (571) 273-8300


\_\_\_\_\_  
Edmund J. Sease

Applicant discloses herewith patents, publications or other information, of which he is aware that he believes may be material to the examination of this application, and in respect of which, there may be a duty to disclose.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 C.F.R. § 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner.

Respectfully submitted,



EDMUND J. SEASE, Reg. No. 24,741  
McKEE, VOORHEES & SEASE, P.L.C.  
801 Grand Avenue, Suite 3200  
Des Moines, Iowa 50309-2721  
Phone No. (515) 288-3667  
Fax No. (515) 288-1338  
**CUSTOMER NO: 22885**

- bja-

Attorneys of Record

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		Application Number	10/532,698
		Filing Date	April 26, 2005
		First Named Inventor	AGGER, Nicolai
		Art Unit	
		Examiner Name	
Sheet 1 of 2	Attorney Docket Number	P07181US0	

U.S. PATENT DOCUMENTS					
Examiner Initials *	Cite No. <sup>1</sup>	Document Number Number - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	US- 3,449,492	06/10/1969	Jensen, Erik H.	
	2	US- 3,989,328	08/05/1975	Beigler et al.	
	3	US- 4,164,568	08/14/1979	Bywater	
	4	US- 4,711,780	12/08/1987	Fahim	
	5	US- 4,839,171	06/13/1989	Nelson	
	6	US- 5,038,396	08/06/1991	Gjerlov	
	7	US- 6,066,341	05/23/2000	Wilson	
	8	US - 6,007,808	12/28/1999	De Haen et al.	
	9	US- 6,365,176 B1	04/02/2002	Bell et al.	
	10	US- 6,391,310 B1	05/21/2002	Empie et al.	
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	11	WO 2004/043451 A1	05/27/2004	Phar-Malett A/S		
	12	PA 2002 01736	06/18/2003	Baggrunds Teknik		
	13	WO 98/42188	10/01/1998	Squires, Meryl		
	14	HU61474	1993	Antal, L., et al.		
	15	0 474 282 B1	03/11/1992	Pharmalett International		
	16	0 382 306 A1	08/16/1990	Duphar International		
	17	WO 85/01441	04/11/1985	GJERLØV, Mogens		
	18	WO 82/ 02650	08/19/1982	Von MAGIUS Niels		
	19	German 2611979	03/19/1976	Mayer, Alois		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

<sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Application Number</b>	10/532,698
		<b>Filing Date</b>	April 26, 2005
		<b>First Named Inventor</b>	AGGER, Nicolai
		<b>Group Art Unit</b>	
		<b>Examiner Name</b>	
		<b>Attorney Docket Number</b>	P07181US0
<b>Sheet</b>	2	<b>of</b>	2

<b>OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS</b>			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	20	Argenzio, Robert A., et al. "Glutamine Stimulates Prostaglandin-Sensitive Na <sup>+</sup> -H <sup>+</sup> Exchange in Experimental Procine Cryptosporidiosis" Gastroenterology 1004;106:1418-1428	
	21	Brooks, H.W., et al. "Evaluation of a Glutamine-containing Oral Rehydration Solution for the Treatment of Calf Diarrhoea using an <i>Escherichia coli</i> Model" The Veterinary Journal 1997, 153, 163-170	
	22	Fettman, Martin J., et al. "Potential Benefits of Psyllium Mucilloid Supplementation of Oral Replacement Formulas for Neonatal Calf Scours" Compendium on Continuing Education for the Practicing Veterinarian, Vol. 14, No. 2, February 1992 247	
	23	Grady, Kevin, "How Basal Media Provide the Optimal Environment for Cell Culture" FOCUS (1999) Vol. 21, No. 3	
	24	Hunt, L., et al. "GFP-Expressing Mammalian Cells for Fast, Sensitive, Noninvasive Cell Growth Assessment in a Kinetic Mode" 1999 John Wiley & Sons, Inc., CCC 0006-3592/99/020201-05	
	25	Naylor, J.M., "Effect of Glutamine or Glycine Containing Oral Electrolyte Solutions on Mucosal Morphology, Clinical and Biochemical Findings, in Calves with Viral Induced Diarrhea" Can J Vet Res 1997; 61:43-48	
	26	<a href="http://ohly.de/sommer.htm">http://ohly.de/sommer.htm</a> Yeast Extracts: Production, Properties and Components; 6 pages	
	27	Antibiotics <a href="http://www.euroclone.net/cell_biology/celb_ccult_ancil.htm">http://www.euroclone.net/cell_biology/celb_ccult_ancil.htm</a> 4/11/2002; 5 pages	
	28	Cell Culture Media Formulations Medium; CMRL Media; 9 pages	

<b>Examiner Signature</b>		<b>Date Considered</b>	
-------------------------------	--	----------------------------	--

\* EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.